What was AbbVie's stock return in 30 days?

AbbVie's stock returned 12.07% in 30 days and 20.35% in 90 days.

Is Tepkinly available now?

It received European Commission marketing authorization and is expected to be available in European markets in the coming months.

What competition does Tepkinly face?

Tepkinly competes with Roche's Mosunetuzumab and Glofitamab, but is the first chemotherapy-free regimen for second-line treatment.

AbbVie Gets EU Approval for Tepkinly in Follicular Lymphoma

AbbVie (ABBV) received European Commission marketing authorization for Tepkinly plus lenalidomide and rituximab in relapsed or refractory follicular lymphoma, the first chemotherapy-free bispecific-based regimen for second-line treatment. The stock has returned 12.07% over 30 days and 20.35% over 90 days.

July 8, 2026

2 min read

Source: Simply Wall St.

Key Numbers

30 day return

12.07%

90 day return

20.35%

The Product

Tepkinly is a bispecific antibody targeting CD20 and CD3, activating T-cells to attack cancer cells. It is administered with lenalidomide and rituximab for patients who have received prior therapy.

Pricing and Availability

AbbVie has not disclosed pricing for Tepkinly yet. It is expected to be available in European markets in the coming months following approval.

Competition

Tepkinly competes with Roche's Mosunetuzumab (Lunsumio) and Glofitamab. However, being the first chemotherapy-free regimen for second-line treatment may give it a competitive edge.

Potential Impact on AbbVie

Tepkinly is expected to bolster AbbVie's oncology portfolio, especially as Humira faces patent expiration. The stock has risen 12.07% in 30 days and 20.35% in 90 days, reflecting investor optimism.

Frequently Asked Questions

Tepkinly is a bispecific antibody targeting CD20 and CD3, used with lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.